M&A Deal Summary

The Medicines Company Acquires ProFibrix B.V.

On June 4, 2013, The Medicines Company acquired life science company ProFibrix B.V. from Gilde Healthcare for 230M USD

Acquisition Highlights
  • This is The Medicines Company’s 3rd transaction in the Life Science sector.
  • This is The Medicines Company’s largest (disclosed) transaction.
  • This is The Medicines Company’s 1st transaction in the Netherlands.

M&A Deal Summary

Date 2013-06-04
Target ProFibrix B.V.
Sector Life Science
Buyer(s) The Medicines Company
Sellers(s) Gilde Healthcare
Deal Type Add-on Acquisition
Deal Value 230M USD
Advisor(s) Barclays Investment Bank (Financial)
Dechert (Legal)

Target

ProFibrix B.V.

Leiden, Netherlands
ProFibrix is a provider of fibrinogen technology to develop and market innovative products for the hemostasis and regenerative medicine markets. Human fibrinogen is a natural blood protein that plays a pivotal role in blood clotting and tissue healing.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

The Medicines Company

Parsippany, New Jersey, United States

Category Company
Founded 1996
Sector Life Science
Employees62
Revenue 6M USD (2018)
DESCRIPTION
Entrance to The Medicines Company's corporate headquarters in Parsippany, New Jersey.
Entrance to The Medicines Company's corporate headquarters in Parsippany, New Jersey.

The Medicines Company is a provider of solutions in acute cardiovascular care, surgery and perioperative care, and serious infectious disease care. The Medicines Company was formed in 1996 and is based in Parsippany, New Jersey. The Medicines was founded in 1996 and is based in Parsippany, New Jersey.


DEAL STATS #
Overall 4 of 6
Sector (Life Science) 3 of 4
Type (Add-on Acquisition) 2 of 4
Country (Netherlands) 1 of 1
Year (2013) 2 of 3
Size (of disclosed) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2013-01-07 Incline Therapeutics

Redwood City, California, United States

Incline Therapeutics, Inc. is a company focused on the development of IONSYS® (fentanyl iontophoretic transdermal system), a compact, disposable, needleless Patient-Controlled Analgesia (PCA) system in development for the short-term management of acute postoperative pain in the hospital setting.

Buy $185M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2013-12-04 Rempex Pharmaceuticals

San Diego, California, United States

Rempex Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery and development of new antibacterial drugs to meet the growing clinical need created by multi-drug resistant bacterial pathogens.

Buy -

Seller(S) 1

SELLER

Gilde Healthcare

Investor Investor Investor Investor Investor


Category Private Equity Firm
Founded 1999
PE ASSETS 2.6B EUR
Size Large
Type Sector Focused
DESCRIPTION

Gilde Healthcare is a specialist private equity and venture investor focused on the healthcare sector. The Firm's buyout group targets majority investments throughout Europe (preference for Germany, the Netherlands, Belgium, Austria or Switzerland) and has a focus on healthcare providers, suppliers and service providers active in the healthcare market. The Firm's venture group looks to invest in early stage medtech, diagnostics, digital health and therapeutics companies throughout North America and Europe. Gilde Healthcare was established in 2001 and is headquartered in Utrecht, the Netherlands.


DEAL STATS #
Overall 8 of 30
Sector (Life Science) 5 of 16
Type (Add-on Acquisition) 5 of 15
Country (Netherlands) 1 of 10
Year (2013) 1 of 2
Size (of disclosed) 4 of 10
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2013-01-01 Sapiens Steering Brain Stimulation

Munich, Germany

Sapiens Steering Brain Stimulation GmbH is developing a Deep Brain Stimulation (DBS) system for patients suffering from brain disorders such as Parkinson’s disease. Sapiens’ innovative solution is an advanced DBS lead with 40 individual stimulation points.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2013-06-14 Conatus Pharmaceuticals

San Diego, California, United States

Conatus Pharmaceuticals is a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease. Conatus Pharmaceuticals was founded in 2005 and is based in San Diego, California.

Sell -